EGFR and adenocarcinoma: EGFR mutations or deletions are one of the most common driver mutations found in NSCLC adenocarcinoma and reliable identification of alterations in EGFR in NSCLC patients is critical to correctly identify patients that will benefit from treatment with tyrosine kinase inhibitors.